PHOTO
Cairo Egypt: Egypt has announced its plans to establish a map of the Egyptian human genome and enter the world of precision medicine, the Egyptian President Abdel Fattah El Sisi has been briefed on the development of the project by Prime Minister Mustafa Mabdouli and Minister of Higher Education Khaled Abdel Ghaffar.
Egypt Today website reported that “The project could help Egypt enter the era of precision medicine, gene therapy, and future specialized drugs based on genetic combinations, according to a statement from the Egyptian Presidency Spokesperson Bassam Radi”.
AGBL Egypt has been selected by the project as the main supplier of technology, under its roles AGBL Egypt will provide support and service for the project per the signed contract with the Egyptian Center for Research and Regenerative Medicine, that will be entrusted to run the project.
Mr Mohamed Abdel Hakim, the Regional Sales Director at AGBL Group commented on the news by saying: “We take great pride in being part of the “Egyptian Genome Project” family, we believe that our expertise with similar large scale products for Population Genomics in the region will enable us to provide the necessary support to this ambitious project”.
About AGBL Egypt
AGBL Egypt is a member of the AGBL group of companies, the largest biomedical distribution group in the Middle East, Africa, and Asia region. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centers in emerging healthcare markets. AGBL Egypt is headquartered in Cairo and covers Egypt and Sudan.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
